Goldman Sachs Maintains Neutral on Singular Genomics Sys, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Neutral rating on Singular Genomics Sys (NASDAQ:OMIC) and lowered the price target from $1.15 to $1.
August 10, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs has maintained a Neutral rating on Singular Genomics Sys and lowered the price target from $1.15 to $1.
The lowering of the price target by Goldman Sachs, a major financial institution, could negatively impact investor sentiment towards Singular Genomics Sys, potentially leading to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100